Safety, Tolerability, and Pharmacokinetics of a Novel Macrocyclic Gadolinium-Based Contrast Agent, HNP-2006, in Healthy Subjects

From the Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul, South Korea (K.Y.H., W.K.C., K.-S.Y., S.H.L.); Hana Pharm Co, Ltd, Seoul, South Korea (H.L.); and Department of Radiology, Seoul National University Hospital, Seoul, South Korea (S.H.C.).

Received for publication April 14, 2023; and accepted for publication, after revision, June 6, 2023.

Conflicts of interest and sources of funding: The study was supported by Hana Pharm Co, Ltd, Seoul, South Korea. H.L. is the employee of Hana Pharm Co, Ltd. The other authors declare no conflict of interest.

Correspondence to: SeungHwan Lee, MD, PhD, Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea. E-mail: [email protected].

Supplemental digital contents are available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (www.investigativeradiology.com).

留言 (0)

沒有登入
gif